Polycystic Ovary Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF9 and BMP15 associations with oocyte number differed significantly (P < 0.05) with PCOS status.
|
31211369 |
2019 |
Polycystic Ovary Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Concentrations of GDF9 showed significantly higher concentrations in PCO FFs of follicles >6 mm.
|
31287539 |
2019 |
Polycystic Ovary Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
The immunoreactivity of growth differentiation factor 9 and bone morphogenetic protein 15 proteins decreased (p<0.05) in the Polycystic ovary syndrome group (27.73±8.43 and 24.85±7.03, respectively) compared with the control group (33.72±11.22 and 31.12±11.05, respectively) and vehicle group (33.95±10.75 and 29.99±10.72, respectively).
|
28903889 |
2018 |
Polycystic Ovary Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we examined the role of ring finger protein 6 (RNF6) in AR ubiquitination and the possible dysregulation in the expression and actions of growth differentiation factor 9 (GDF9) and kit-ligand (Kitlg) in a chronic androgenized PCOS rat model.
|
28860512 |
2017 |
Polycystic Ovary Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fourteen mutations in human (h) GDF9 have been reported in women with premature ovarian failure or polycystic ovarian syndrome as well as in mothers of dizygotic twins, implicating GDF9 in the etiology of these conditions.
|
24438375 |
2014 |
Polycystic Ovary Syndrome
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In Graafian follicles, GDF9 and BMP15 expression reached comparable levels in the PCOS and control groups (P > 0.05).
|
25172094 |
2014 |
Polycystic Ovary Syndrome
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The abundance of GDF9 mRNA was significantly lower (P < 0.01) while the abundance of BMP15 mRNA was significantly higher (P < 0.001) in GCs from stimulated-PCOS group than in unstimulated-PCOS group.
|
23912750 |
2013 |
Polycystic Ovary Syndrome
|
0.400 |
Biomarker
|
disease |
CTD_human |
We inferred that BMP15 and GDF9 transcript levels increase in mature PCOS oocytes after COH, and might inhibit the progesterone secretion by follicular cells in PCOS follicles, preventing premature luteinization in cumulus cells.
|
22825968 |
2012 |
Polycystic Ovary Syndrome
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We inferred that BMP15 and GDF9 transcript levels increase in mature PCOS oocytes after COH, and might inhibit the progesterone secretion by follicular cells in PCOS follicles, preventing premature luteinization in cumulus cells.
|
22825968 |
2012 |
Polycystic Ovary Syndrome
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Abnormal expression of growth differentiation factor 9 and bone morphogenetic protein 15 in stimulated oocytes during maturation from women with polycystic ovary syndrome.
|
21669410 |
2011 |
Polycystic Ovary Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The above-mentioned mutations indicate GDF9 may be potentially associated with PCOS patients.
|
20705511 |
2010 |
Polycystic Ovary Syndrome
|
0.400 |
Biomarker
|
disease |
BEFREE |
Certain GDF9 variants were associated with hirsutism scores and parity in PCOS patients.GDF9 may thus serve as a modifier gene.
|
20236105 |
2010 |
Polycystic Ovary Syndrome
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, the expression of GDF-9 in cumulus GCs of patients with PCOS was decreased significantly compared with controls (8.88 +/- 1.52 vs. 5.01 +/- 0.83).
|
19376510 |
2010 |
Polycystic Ovary Syndrome
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To address this issue, we compared the pattern and level of expression of GDF-9 and BMP-15 mRNA in ovaries from normal cycling (n = 12), PCOS (n = 5), and PCO (n = 7) patients.
|
11889206 |
2002 |
Polycystic Ovary Syndrome
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The missense mutation in the GDF-9 gene or the GDF-9B/BMP-15 gene is uncommon in anovulatory Japanese women with POF and PCOS.
|
11056243 |
2000 |